ResearcherUniversity of BernActive in the last 2 years

Maciej Garczyk

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5130916424. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2026: 2 papers

Papers 2

Targeting PI3Kδ suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion. Co-author DOI 10.1016/j.celrep.2026.117188 ↗
Targeting PI3Kδ suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion. Co-author DOI 10.1016/j.celrep.2026.117453 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Martin Wartenberg · 2 shared papers, 2026 · strength 0.47
- Paper Targeting PI3Kδ suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion. DOI 10.1016/j.celrep.2026.117188 ↗
- Paper Targeting PI3Kδ suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion. DOI 10.1016/j.celrep.2026.117453 ↗
Matteo Rossi Sebastiano · 2 shared papers, 2026 · strength 0.47
- Paper Targeting PI3Kδ suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion. DOI 10.1016/j.celrep.2026.117188 ↗
- Paper Targeting PI3Kδ suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion. DOI 10.1016/j.celrep.2026.117453 ↗
Beat Gloor · 2 shared papers, 2026 · strength 0.47
- Paper Targeting PI3Kδ suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion. DOI 10.1016/j.celrep.2026.117188 ↗
- Paper Targeting PI3Kδ suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion. DOI 10.1016/j.celrep.2026.117453 ↗
Georgia Konstantinidou · 2 shared papers, 2026 · strength 0.47
- Paper Targeting PI3Kδ suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion. DOI 10.1016/j.celrep.2026.117188 ↗
- Paper Targeting PI3Kδ suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion. DOI 10.1016/j.celrep.2026.117453 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.